Breast cancer is a clinically, pathologically, histologically, and prognostically complex disease and the classification that is important to determine treatment and the future outcome is based on analysis of the estrogen receptor (ER), the progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and proliferation marker (Ki67). Here, ERBB2 is linked to breast carcinoma.